The abstract is read at the publisher; the summary is JClub's.
In transplant-eligible newly diagnosed multiple myeloma patients ≤65, KRd-ASCT with carfilzomib-lenalidomide-dexamethasone achieved longer progression-free survival (median 98 months) than KRd12 (70) and KCd-ASCT (67).
- Why it matters: Long-term evidence is needed to confirm whether carfilzomib-based induction, transplant strategy, and maintenance translate into durable disease control and survival benefits.
- What they did: In the phase 2 FORTE trial, patients were randomized to KRd-ASCT, KRd12, or KCd-ASCT, then re-randomized to maintenance with carfilzomib plus lenalidomide for 2 years or lenalidomide alone until progression; follow-up was median 99 months from R1 and 85 months from R2.
- The result: KRd-ASCT improved PFS versus both comparators (HR 0.71, p=0.027; HR 0.66, p=0.006) and improved PFS2 and overall survival versus KCd-ASCT (8-year OS 76% vs 68%; HR 0.65, p=0.04), while KR maintenance improved PFS versus R (HR 0.67, p=0.02) without PFS2/OS differences.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.